Cross-practice team advises European market leader for established medicines on the transaction

Frankfurt, 12 October 2026 - Latham & Watkins LLP has advised Cheplapharm Arzneimittel GmbH (Cheplapharm), a European market leader for established medicines, on its seven-year Term Loan B of EUR 1.2 billion. The proceeds will be used to partially refinance Cheplapharm's existing EUR 1.28 billion Term Loan B due 2029.

The refinancing follows Cheplapharm's recently announced strategic partnership with Sanofi. Earlier this year, Cheplapharm also issued EUR 950 million 6.75% Senior Secured Notes due 2032. Latham & Watkins advised Cheplapharm on both transactions.

Berater Latham & Watkins:

Jan Penselin (Capital Markets), Alexandra Hagelüken (beide Partner), Cora Grannemann (Counsel, gemeinsame Federführung), Yan Ma (Associate, alle Banking & Private Credit), Peter Neuböck, Tobias Müller (beide Associate, Capital Markets, alle Frankfurt)

This text was automatically translated from the German original.